BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32210275)

  • 1. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
    Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
    Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
    Turnbull AP; Ioannidis S; Krajewski WW; Pinto-Fernandez A; Heride C; Martin ACL; Tonkin LM; Townsend EC; Buker SM; Lancia DR; Caravella JA; Toms AV; Charlton TM; Lahdenranta J; Wilker E; Follows BC; Evans NJ; Stead L; Alli C; Zarayskiy VV; Talbot AC; Buckmelter AJ; Wang M; McKinnon CL; Saab F; McGouran JF; Century H; Gersch M; Pittman MS; Marshall CG; Raynham TM; Simcox M; Stewart LMD; McLoughlin SB; Escobedo JA; Bair KW; Dinsmore CJ; Hammonds TR; Kim S; Urbé S; Clague MJ; Kessler BM; Komander D
    Nature; 2017 Oct; 550(7677):481-486. PubMed ID: 29045389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.
    Saha G; Sarkar S; Mohanta PS; Kumar K; Chakrabarti S; Basu M; Ghosh MK
    Oncogene; 2022 Nov; 41(47):5061-5075. PubMed ID: 36243803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP7: Target Validation and Drug Discovery for Cancer Therapy.
    Zhou J; Wang J; Chen C; Yuan H; Wen X; Sun H
    Med Chem; 2018; 14(1):3-18. PubMed ID: 29065837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.
    Colland F; Formstecher E; Jacq X; Reverdy C; Planquette C; Conrath S; Trouplin V; Bianchi J; Aushev VN; Camonis J; Calabrese A; Borg-Capra C; Sippl W; Collura V; Boissy G; Rain JC; Guedat P; Delansorne R; Daviet L
    Mol Cancer Ther; 2009 Aug; 8(8):2286-95. PubMed ID: 19671755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
    Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
    Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
    Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
    Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
    Le Clorennec C; Lee K; Huo Y; Zage PE
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy.
    Nininahazwe L; Liu B; He C; Zhang H; Chen ZS
    Drug Discov Today; 2021 Feb; 26(2):490-502. PubMed ID: 33157193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP7 small-molecule inhibitors interfere with ubiquitin binding.
    Kategaya L; Di Lello P; Rougé L; Pastor R; Clark KR; Drummond J; Kleinheinz T; Lin E; Upton JP; Prakash S; Heideker J; McCleland M; Ritorto MS; Alessi DR; Trost M; Bainbridge TW; Kwok MCM; Ma TP; Stiffler Z; Brasher B; Tang Y; Jaishankar P; Hearn BR; Renslo AR; Arkin MR; Cohen F; Yu K; Peale F; Gnad F; Chang MT; Klijn C; Blackwood E; Martin SE; Forrest WF; Ernst JA; Ndubaku C; Wang X; Beresini MH; Tsui V; Schwerdtfeger C; Blake RA; Murray J; Maurer T; Wertz IE
    Nature; 2017 Oct; 550(7677):534-538. PubMed ID: 29045385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
    Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
    J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity.
    He Y; Li W; Lv D; Zhang X; Zhang X; Ortiz YT; Budamagunta V; Campisi J; Zheng G; Zhou D
    Aging Cell; 2020 Mar; 19(3):e13117. PubMed ID: 32064756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Potent and Selective Degrader for USP7.
    Pei Y; Fu J; Shi Y; Zhang M; Luo G; Luo X; Song N; Mi T; Yang Y; Li J; Zhou Y; Zhou B
    Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202204395. PubMed ID: 35691827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.
    Li P; Liu Y; Yang H; Liu HM
    Eur J Med Chem; 2021 Apr; 216():113291. PubMed ID: 33684824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HAUSP in both p53 wildtype and p53-mutant tumors.
    Tavana O; Sun H; Gu W
    Cell Cycle; 2018; 17(7):823-828. PubMed ID: 29616860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
    Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
    Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60.
    Wang F; Wang L; Wu J; Sokirniy I; Nguyen P; Bregnard T; Weinstock J; Mattern M; Bezsonova I; Hancock WW; Kumar S
    PLoS One; 2017; 12(12):e0189744. PubMed ID: 29236775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ubiquitin specific protease 7 in cancer: A deubiquitinase with great prospects.
    Yeasmin Khusbu F; Chen FZ; Chen HC
    Cell Biochem Funct; 2018 Jul; 36(5):244-254. PubMed ID: 29781103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.